

PRESS RELEASE

STOCKHOLM, OCTOBER 2, 2023

Paul Scherrer Institute selects RayStation

RaySearch Laboratories AB (publ) is pleased to announce that the Paul Scherrer Institute (PSI) in Switzerland has placed an order for the treatment planning system RayStation®*.

Renowned worldwide for its treatment of cancers with proton therapy, PSI has selected RayStation as the treatment planning system for its clinical operations. PSI is equipped with three gantries and a fixed horizontal beam line room for ocular treatments. Two of the gantries, of which one is in-house developed, operate clinically while the third is dedicated to research.

Alongside the procurement of RayStation, RaySearch and PSI have the intent of engaging in a collaborative research initiative. This partnership will focus on a range of strategic areas, including online adaptive proton therapy.

Damien C. Weber, Chairman of the proton Therapy Center, Paul Scherrer Institute, says: "By combining proton therapy with advanced treatment planning system as proposed by RaySearch, we can push the boundaries of optimal cancer care. We look forward to collaborating with one of the leading developers of treatment planning systems to share our expertise in proton therapy and advance research in various areas, including but not limited to treatment plan adaptation."

Johan Löf, founder and CEO, RaySearch, says: "PSI is an exceptional place to treat cancer, and I am proud to welcome them as customers. It is also very exciting to engage in several research projects together with a partner with such strong research capabilities. This will be beneficial for the next generation of RayStation as well as an important step in fulfilling our vision of a world where cancer is conquered."

About PSI

The Paul Scherrer Institute PSI develops, builds, and operates large, complex research facilities and makes them available to the national and international research community. The institute's own key research priorities are in the fields of future technologies, energy and climate, health innovation and fundamentals of nature. PSI employs 2,200 people, thus being the largest research institute in Switzerland. The annual budget amounts to approximately CHF 420 million. PSI is part of the ETH Domain.

About RaySearch

RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system which enables cancer



clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.

RaySearch's software has been sold to over 900 clinics in more than 40 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at raysearchlabs.com.

About RayStation

RayStation®* is a flexible, innovative treatment planning system, chosen by many leading cancer centers worldwide. It combines unique features such as unmatched adaptive therapy capabilities, multi-criteria optimization, market-leading algorithms for treatment plan optimization for HDR brachytherapy and external beam therapy with photons, electrons, and protons, as well as helium and carbon ions. RayStation supports a wide range of treatment machines, providing one control center for all treatment planning needs and ensuring centers get greater value from existing equipment. RayStation also seamlessly integrates with RayCare®*. By harmonizing the treatment planning, the care of cancer patients worldwide is improved.

For more information, please contact:

Johan Löf, founder and CEO, RaySearch Laboratories AB (publ) Telephone: +46 (0) 8 510 530 00

johan.lof@raysearchlabs.com

^{*} Subject to regulatory clearance in some markets.